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health-insured patients: from the 4th day of disability, the Instituto Mexicano del 
Seguro Social covers 60% of wages, 2) Private health-insured: economical loss of 
private beneficiaries is a 20% co-pay plus daily average income lost. 3) No-health-
insurance: Medical costs and absenteeism represent the economical loss. Costs are 
expressed in 2014 USD (1USD= 13MXN). Morbidity cases were extracted from pub-
lished data by National Institute of Public Health and used to calculate a weighted 
average of economical losses for each scenario. Results: The distribution of 
people with smoking-related disease (AMI, COPD and LC) was 25.0%, 65.4% and 
9.6%, respectively. Patients in scenario 1) 2) and 3) spend/lose an average of $446.6, 
$8,448.2 and $37,384.95 per year, respectively (medical costs are the drivers of the 
economic resources lost by not-insured population). Average illness expense derived 
from tobacco consumption regarding the proportion of people in each scenario 
was $13,917 yearly (local per capita GDP is $9,749). Regardless of health-insurance 
status, LC is the most expensive disease ($39,564.26), followed by AMI and COPD 
($14,337.06 and $10,109.32, respectively). ConClusions: The study showed that in 
the long run smokers incur significant economic losses even if they have medical 
insurance. Costs increases to people that do not have any insurance.
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objeCtives: To assess and compare the costs of first-line monoclonal antibodies 
(mABs) treatment protocols in breast cancer, non-Hodgkin lymphoma and colo-
rectal carcinoma in South-Εastern Europe. Methods: A retrospective, bottom-up 
case series study design was implemented with one-year time horizon and payer’s 
perspective. The study sample size was 265 patients (breast cancer, N= 137, colorec-
tal cancer, N= 44, and non-Hodgkin lymphoma, N= 84) while treatment protocols 
included adjuvant mAbs: trastuzumab (N= 137), bevacizumab (N= 28), cetuximab 
(N= 16) and rituximab (N= 84). ICD-10 related, direct medical and lost productivity 
costs (€ ) across treatment groups during 2010-2013. Results: The average length 
of observation was 128±97 days per patient. Total mean direct and indirect costs 
of care were: trastuzumab breast cancer group € 17,740; bevacizumab colorectal 
carcinoma group € 8,775; cetuximab colorectal carcinoma group € 27,181 and rituxi-
mab non-Hodgkin lymphoma group € 19,431. An average mAbs-treated patient 
incurred € 17,897 costs of medical care. The total combined budget of these 265 
patients was € 4,742,775. ConClusions: The use of mAbs strongly correlated with 
high costs in first-line cancer medical care and dominated other cost domains. 
Cetuximab-based treatment protocol in colorectal carcinoma patients was sub-
stantially more expensive compared to trastuzumab (C50); bevacizumab (C20) 
and rituximab (C80) alternatives. Extremely high costs of mAbs are the key-issue 
for Eastern European policy makers by crossing the upper limits of affordability 
in middle-income economies.
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objeCtives: Isolated limb perfusion and infusion (ILP/ILI) are therapies for region-
ally metastatic melanoma where high doses of anticancer drugs are delivered 
directly into the circulation of an affected limb, while minimizing systemic drug 
exposure. This procedure can lead to high response rates but without proven ben-
efits to overall survival. It is recommended by ESMO and NCCN guidelines as a treat-
ment option for patients with stage III unresectable metastatic melanoma. However, 
limited information is available on its use pattern and costs in the literature. This 
study was to examine patterns of ILP/ILI use and associated costs in patients with 
melanoma in the US. Methods: This is a retrospective, observational study using 
large administrative claims from the MarketScan® databases. Patients who under-
went ILP/ILI (CPT-4: 36823) with diagnosis of melanoma (ICD-9-CM: 172. xx, V10.82) 
between 1/1/2002 and 3/31/2013 were included. Patient characteristics, use patterns, 
hospital length of stay, and costs (2013 US $) of ILP/ILI were assessed. Results: 
A total of 113 patients met the study criteria and were included in the analysis. The 
mean age was 62.1 years (standard deviation [SD] 14.1); 39.8% were male. The mean 
baseline Charlson’s comorbidity index was 0.24 and 36.4% of patients were Medicare 
beneficiaries. Overall, 86.4% of patients had melanoma in the lower limb, 12.7% in 
the upper limb, and 0.9% in both upper and lower limbs; 59.3% had lymph node 
metastasis and 56.8% had skin metastasis. Four patients (3.5%) underwent multiple 
ILP/ILI procedures. The mean (±SD) hospital length of stay was 5.6 (± 3.5) days and 
the mean (±SD) cost was $35,898 (± $26,492) per ILP/ILI procedure. ConClusions: 
The use of isolated limb perfusion and infusion was associated with relatively long 
hospital stay and high cost. The results of this study may provide source data for 
economic evaluations of treatment options for regionally metastatic melanoma.
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objeCtives: To estimate the resource use and costs a health plan can anticipate 
during the diagnosis, treatment, and surveillance of a patient with metastatic unre-
for France and Germany in year 1 and 2, were € 502 - € 126 for France; € 1,429 - € 1,156 
for Germany. Total costs reached € 18,024 (yr1), € 7,039 (yr2) France; € 19,025 (yr1), 
€ 13,295 (yr2) Germany; € 15,785 (yr1), € 1,990 (yr2) England. Two-year costs totalled 
€ 25,063 (France); € 32,500 (Germany); € 17,777 (England). Subgroup analyses showed 
higher costs for elderly patients, those with non-metastatic disease and smokers.  
ConClusions: Considerable differences in average treatment costs were observed. 
In-patient costs dominate in the first year of treatment in all countries. The study 
highlights the costly nature of NSCLC.
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objeCtives: Best supportive care (BSC) is in general individually provided to 
patients. Thus, the scope of BSC and its costs can vary widely. Only limited 
information on BSC costs for patients with non-small cell lung cancer (NSCLC) 
exists. Aim of this research was to estimate annual BSC costs for NSCLC patients 
in Germany. Methods: To estimate BSC costs at first a literature search in 
PubMed with the key words “best supportive care”, “cost”, “non-small cell lung 
cancer” and “economic analysis” individual and combined search terms was 
performed. International publications of economic evaluations including data 
on single cost items which could be applied to the German health care system 
were included. Additionally, data on BSC from a NSCLC patient registry (n= 193) 
and prescription data derived from a randomised controlled trial (RCT) were used 
as further references. Cost- items were extracted from each reference and finally 
applied to the German inpatient and outpatient reimbursement system. Results: 
The literature research yielded 317 records of which 3 met the inclusion crite-
ria (2= UK; 1= North America). An extrapolation of these evaluation results to the 
German health care system showed that BSC costs based on UK data ranged 
from 16,940€ to 45,426€ (North America: 31,352€ ). According to health economic 
data from an RCT annual cost for BSC amounted to 17,531€ , while data from a 
NSCLC patient registry added up to 28,070€ . The average annual costs for BSC 
were estimated at 27,864€ . ConClusions: Since BSC is individually delivered 
to patients, it leads to a high variance of annual BSC costs for NSCLC patients in 
Germany. Furthermore, international economic evaluations were extrapolated 
to the German health care system. Hence, results should be interpreted with 
caution as international treatment guidelines and reimbursement schemes are 
not fully applicable to Germany. Future analyses should be based on a German 
population only.
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objeCtives: Treatment for breast cancer is usually based on chemotherapy 
and radiotherapy, but in unsuccessful cases, mastectomy is required. In Brazil, 
mastectomies are performed as simple or radical, with lymphadenectomy. This 
study aims to relate geographic distribution, temporal trends and economic profile 
of this procedure in Brazil. Methods: Assessments about hospital admissions 
were performed to analyze costs and geographic distribution among mastectomies 
related with breast cancer realized in Brazil, from January 2008 to December 2012. 
The data used were extracted by Brazilian Hospital Information System (SIH/SUS) 
database, according to ICD-0416120032 (simple mastectomy) and ICD-0416120024 
(radical with lymphadenectomy). Costs were estimated in 2014 Brazilian Real (BRL) 
and represents federal reimbursement values for hospitalizations (exams, drugs, 
medical procedures and fees). Results: In Brazil, the number of mastectomies 
related with breast cancer ranged from 8,687 in 2008 to 9,703 in 2012. In Southeast 
region were performed 22,977 procedures, which was the largest number per 
region, compared with 1,814 in North; 8,443 in South; 2,280 in Midwest and 10,538 
in Northwest. In São Paulo; 10,111 procedures occurred in this period, while 8 were 
performed in Amapá. Total costs with mastectomies due to breast cancer in Brazil 
during this period were 44,219,235.66 BRL. The value per patient increased about 
12,5% over the years with mean costs from 2008 to 2012 of 799.75BRL, 842.62BRL, 
845.28BRL, 878.20BRL and 870.25BRL, respectively. In 2010, the mean mortality rate 
among simple and radical mastectomies was 0,22% and increased until 0,54% in 
2012. ConClusions: Geographic distribution of mastectomy due to breast cancer 
in Brazil is concentrated in Southeast region, in comparison to other regions and 
from 2008 to 2012 there was no change in this pattern. Although costs elevated, 
mortality also increased in this period.
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objeCtives: Few data has been published in Mexico related to direct smoking 
costs from the consumer perspective. To estimate lost income and pocket costs 
related to smoking diseases from the perspective of Mexican families. Methods: 
The analysis incorporated patients with public, private and no-health insurance 
from 18-65 years. Through Mexican literature review, medical costs and prevalence 
of 3 major diseases associated with tobacco consumption were identified: acute 
myocardial infarction (AMI), chronic obstructive pulmonary disease (COPD) and lung 
cancer (LC) as well as absenteeism associated to each disease. Average income was 
extracted from 2012 national income survey. Scenarios evaluated were: 1) Publicly 
